Statistics
Publications
12
Citations
2.9K
H-Index
11
Active since
2011
Dave Lugo is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, pharmacology, and chromatin.
Publications per year
2011–2024
12
12
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson, Rab K. Prinjha, Antje Dittmann et al. · Nature · 2011 · 1.5K citations · Full text
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong, Omer Gilan, Enid Y.N. Lam et al. · Nature · 2015 · 548 citations · Full text
Medicine, Cancer Biology, Oncology +14
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
S. Picaud, O. Fedorov, Angeliki Thanasopoulou et al. · Cancer Research · 2015 · 230 citations · Full text
Medicine, Oncology, Pharmacology +13
Click chemistry enables preclinical evaluation of targeted epigenetic therapies
Dean Tyler, Johanna Vappiani, Tatiana Cañeque et al. · Science · 2017 · 143 citations · Full text
Medicine, Oncology, Pharmacology +17
Functional interdependence of BRD4 and DOT1L in MLL leukemia
Omer Gilan, Enid Y.N. Lam, Isabelle Becher et al. · Nature Structural & Molecular Biology · 2016 · 124 citations · Full text
1–5 of 12